Supernus Pharmaceuticals
Quarterly Financials
| Values in thousands | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|
Revenue | $165,453 | $149,824 | $174,159 | $175,689 |
Gross Profit | 127,307 | 134,061 | 148,061 | 138,018 |
EBITDA | 37,988 | 17,787 | 45,227 | 65,031 |
EBIT | 16,669 | -2,596 | 26,382 | 44,929 |
Net Income | 22,499 | -11,827 | 15,328 | 38,497 |
Net Change In Cash | 165,453 | 149,824 | 174,159 | 175,689 |
Free Cash Flow | 58,080 | 30,272 | 44,193 | 53,320 |
Cash | 144,711 | 115,848 | 69,331 | 31,673 |
Basic Shares | 56,643 | 55,865 | 56,465 | 56,016 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $661,817 | $607,521 | $667,238 | $579,775 |
Gross Profit | 583,911 | 523,742 | 580,017 | 504,714 |
EBITDA | 178,284 | 90,043 | 153,443 | 129,187 |
EBIT | 97,870 | 5,184 | 67,813 | 96,598 |
Net Income | 73,865 | 1,316 | 60,711 | 53,424 |
Net Change In Cash | 661,817 | 607,521 | 667,238 | 579,775 |
Cost of Revenue | -110,314 | -85,206 | ||
Free Cash Flow | 171,226 | 110,534 | 116,414 | 125,082 |
Cash | 69,331 | 75,054 | 93,120 | 203,434 |
Basic Shares | 55,959 | 55,506 | 61,679 | 54,356 |
Earnings Calls
| Quarter | EPS |
|---|---|
2025-09-30 | $0 |
2025-06-30 | $0.40 |
2025-03-31 | $0.43 |
2024-12-31 | $0.54 |
